Effect of efonidipine hydrochloride (NZ-105) , a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits
Toyoda, K.; Kitahara, M.; Yamashita, T.; Shudo, C.; Masuda, Y.; Sakashita, M.; Tanaka, S.; Saito, Y.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 103(5): 231-239
1994
ISSN/ISBN: 0015-5691 PMID: 8188119 Document Number: 422574
We studied the effect of efonidipine hydrochloride (NZ-105:(+-)-2-(benzyl(phenyl) amino) ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethanol), a newly synthesized dihydropyridine calcium antagonist, on atherosclerosis in 1% cholesterol-fed rabbits. NZ-105 (10, 30 and 100 mg/kg) was orally administrated to the animals twice a day for 10 weeks. NZ-105 did not cause any significant change in the plasma lipid levels. The area of atherosclerotic lesion was reduced by 37% (P lt 0.05) in the aortic arch and by 54% (P gt 0.05) in the thoracic aorta of rabbits administrated 100 mg/kg of NZ-105. The content of cholesterol ester in the aorta was also reduced by 64% (P lt 0.05) in the aortic arch and by 73% (P gt 0.05) in the thoracic aorta. These results suggest that NZ-105 may suppress the development of atherosclerosis without affecting the plasma lipids.